Search Results for “FDA” – Page 180 – media

Gilead Sciences to Acquire Cell Design Labs for $567 Million

Gilead Sciences, Inc. GILD and its newly acquired cell therapy subsidiary -Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares which are owned by Kite Pharma.
- Source: qc.nasdaq
- 423
- December 11, 2017
Apple’s First Medical Study Signals Broader Health Ambitions

Medical researchers are increasingly turning to mobile devices such as smartphones and watches as a way to monitor patients in trials, an approach they hope improves participation and accuracy but that also has limitations.
- Source: wsj
- 555
- December 11, 2017
heart rhythms mobile device Researches
More than 2,000 immune-oncology drugs now in development

A new report has found that there are more than 2,000 immunotherapy drugs now in development for cancer, with 940 of these in clinical stage development and 1,064 at the preclinical stage.
- Source: pharmatimes
- 473
- December 11, 2017
immuno-oncology immunotherapy drugs immuotherapy agents
electroCore completes $70 million series B funding round

electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, has announced it completed its Series B financing that has brought in just over $70 million of capital to the company.
- Source: globalbiotechinsights
- 522
- December 8, 2017
headache Market Views neuromodulation Series
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 622
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 552
- December 8, 2017
CAR–T Market Views Series
Cambridge’s Exonics Therapeutics Scores $40M

Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
- Source: biospace
- 530
- December 7, 2017
DMD Market Views neuromuscular Series
Gottlieb Says Faster Cancer Drug Approvals Coming for Secondary Indications

US Food and Drug Administration (FDA) Commissioner Scott Gottlieb and NIH Director Francis Collins testified on Thursday before the House Energy & Commerce Committee on how their agencies have worked to implement provisions from the 21st Century Cures Act passed and signed by President Barack Obama a month before he left office.
- Source: raps.org
- 682
- December 4, 2017
cancer FDA NIH Policy
Ddu Attended CPhI India

CPhI India was held from November 28th to November 30th, 2017 at the Bombay Exhibition Centre in Mumbai, India.
- Source: Ddu
- 1,424
- December 4, 2017
CPhI pharmaceutical
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data

The frontrunner in the race to commercialize CGRP migraine medications just picked up some added momentum. Amgen $AMGN has published promising Phase III data that might lend to its approval, keeping the company — and its partner Novartis — ahead of its many competitors in the crowded space.
- Source: Endpts
- 506
- December 1, 2017
Aimovig Clinical Trials Phase

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.